Anti-Factor Xa Plasma Levels in Pregnant Women Receiving Low Molecular Weight Heparin Thromboprophylaxis

被引：2
|
作者：
Pabinger, Ingrid [1 ]
Greinacher, Andreas [2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Clin Div Haematol & Haernostaseol, Vienna, Austria
[2] Ernst Moritz Arndt Univ Greifswald, Dept Transfus Med, Inst Immunol & Transfus Med, Greifswald, Germany
来源：
OBSTETRICS AND GYNECOLOGY | 2009年 / 113卷 / 03期
关键词：
VENOUS THROMBOEMBOLISM;
D O I：
10.1097/AOG.0b013e31819b3b38
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：740 / 740
页数：1
相关论文
共 50 条
  • [41] Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins
    Harris, Leanne F.
    Castro-Lopez, Vanessa
    Hammadi, Nissrin
    O'Donnell, James S.
    Killard, Anthony J.
    [J]. TALANTA, 2010, 81 (4-5) : 1725 - 1730
  • [42] Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children
    Greene, L. A.
    Law, C.
    Jung, M.
    Walton, S.
    Ignjatovic, V.
    Monagle, P.
    Raffini, L. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) : 1554 - 1557
  • [43] Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study
    Hakeam, Hakeam A.
    Al Duhailib, Zainab
    Alsemari, Muhannad
    Alwaibah, Reem M.
    Al Shannan, Madhawi F.
    Shalhoub, Munirah
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [44] Chemoenzymatic Synthesis of Heparin Oligosaccharides with both Anti-factor Xa and Anti-factor IIa Activities
    Xu, Yongmei
    Pempe, Elizabeth H.
    Liu, Jian
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (34) : 29054 - 29061
  • [45] Anti-Factor Xa Assay-A Changing Standard for Venous Thromboprophylaxis?
    Cook, Kristin
    Napolitano, Massimo
    Padberg, Frank T., Jr.
    [J]. JAMA SURGERY, 2016, 151 (11) : 1014 - 1014
  • [46] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [47] Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function
    Shomer, Einat
    Katzenell, Sarah
    Zipori, Yaniv
    Rebibo-Sabbah, Annie
    Brenner, Benjamin
    Aharon, Anat
    [J]. THROMBOSIS RESEARCH, 2016, 137 : 141 - 147
  • [48] Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
    Tahaineh, Linda
    Edaily, Sahar M.
    Gharaibeh, Shadi F.
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 63 - 70
  • [49] The influence of low molecular weight heparin medication on plasma DNA in pregnant women
    Groemminger, Sebastian
    Erkan, Sanli
    Schoeck, Ulrike
    Stangier, Kerstin
    Bonnet, Joachim
    Schloo, Ruediger
    Schubert, Angela
    Prott, Eva-Christina
    Knoll, Ute
    Stumm, Markus
    von Kalle, Christof
    Hofmann, Wera
    [J]. PRENATAL DIAGNOSIS, 2015, 35 (11) : 1155 - 1157
  • [50] Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol
    Williams-Norwood, Tanya
    Caswell, Megan
    Milner, Barbara
    Vescera, Joseph C.
    Prymicz, Kelly
    Ciszak, Amy G.
    Ingle, Carol
    Lacey, Christopher
    Stavrou, Evi X.
    [J]. AACN ADVANCED CRITICAL CARE, 2020, 31 (02) : 129 - 137
12345